Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDe La Rue Regulatory News (DLAR)

Share Price Information for De La Rue (DLAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 96.80
Bid: 96.00
Ask: 97.00
Change: 0.60 (0.62%)
Spread: 1.00 (1.042%)
Open: 93.40
High: 96.80
Low: 93.40
Prev. Close: 96.20
DLAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) (De La Rue)

14 Dec 2010 12:45

RNS Number : 9332X
De La Rue PLC
14 December 2010
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the party to the offer making the disclosure:

DE LA RUE PLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each party to the offer

DE LA RUE PLC

(d) Is the party to the offer making the disclosure the offeror or the offeree?

OFFEREE

(e) Date position held:

13 DECEMBER 2010

(f) Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

NO

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

ordinary shares of 44 152/175 pence each

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

N/A

N/A

(2) Derivatives (other than options):

N/A

N/A

(3) Options and agreements to purchase/sell:

N/A

N/A

 

TOTAL:

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

 

 

 

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(c) Irrevocable commitments and letters of intent

 

Details of any irrevocable commitments or letters of intent procured by the party to the offer making the disclosure or any person acting in concert with it (see Note 3 on Rule 2.11 of the Code):

 

N/A

 

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe of any person acting in concert with the party to the offer making the disclosure:

 

The directors of De La Rue plc have the following interests in ordinary shares of 44 152/175p each in the capital of De La Rue plc

 

Interests

No of Shares Percentage of issued share capital

Nicholas Brookes 7,780 0.0078

Warren East 2,093 0.0021

Gill Rider 454 0.0004

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3 for each additional class of relevant security.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

14 December 2010

Contact name:

Ed Peppiatt

Telephone number:

01256 605296

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEDMMMZZDZGGZM
Date   Source Headline
30th May 20247:00 amRNSStrategic Update
2nd May 202411:39 amRNSHolding(s) in Company
17th Apr 20247:00 amRNSPre-Close Trading Statement
16th Apr 202411:52 amRNSHolding(s) in Company
16th Apr 202410:59 amRNSHolding(s) in Company
3rd Apr 20247:00 amRNSExtension of contract with Microsoft
2nd Apr 202411:25 amRNSTotal Voting Rights
7th Mar 20241:04 pmRNS2023 AGM Voting Update
23rd Feb 20242:06 pmRNSAdditional Listing
29th Jan 20244:14 pmRNSHolding(s) in Company
26th Jan 20244:38 pmRNSDirector/PDMR Shareholding
18th Jan 20243:19 pmRNSHolding(s) in Company
18th Jan 202412:13 pmRNSHolding(s) in Company
2nd Jan 202411:33 amRNSBlock listing Interim Review
21st Dec 20233:51 pmRNSHolding(s) in Company
19th Dec 20237:00 amRNS2023/24 half year results
27th Nov 20232:53 pmRNSHolding(s) in Company
1st Nov 20231:51 pmRNSTotal Voting Rights
30th Oct 202311:05 amRNSHolding(s) in Company
13th Oct 202310:27 amRNSDirector/PDMR Shareholding
6th Oct 20237:00 amRNSPre-close Trading Statement
2nd Oct 202311:47 amRNSTotal Voting Rights
20th Sep 202312:59 pmRNSDirector/PDMR Shareholding
13th Sep 20231:09 pmRNSHolding(s) in Company
7th Sep 20231:59 pmRNSResult of AGM
7th Sep 20237:00 amRNSAGM statement and trading update
4th Sep 202312:36 pmRNSHolding(s) in Company
1st Sep 20231:15 pmRNSTotal Voting Rights
14th Aug 20233:30 pmRNSHolding(s) in Company
11th Aug 20232:58 pmRNSHolding(s) in Company
11th Aug 20237:00 amRNSDirectorate Change
4th Aug 20237:00 amRNSDirectorate Change
3rd Aug 20239:21 amRNSAppointment of Joint Broker
2nd Aug 20233:26 pmRNSDirector/PDMR Shareholding
1st Aug 20239:00 amRNSTotal Voting Rights
28th Jul 20231:44 pmRNSDirector/PDMR Shareholding
24th Jul 20233:04 pmRNSHolding(s) in Company
20th Jul 20234:03 pmRNSHolding(s) in Company
20th Jul 202312:17 pmRNSAnnual Financial Report
19th Jul 20231:01 pmRNSHolding(s) in Company
11th Jul 202310:28 amRNSDirector/PDMR Shareholding
4th Jul 202312:59 pmRNSHolding(s) in Company
3rd Jul 20235:44 pmRNSHolding(s) in Company
3rd Jul 202312:12 pmRNSBlock listing Interim Review
3rd Jul 202312:09 pmRNSTotal Voting Rights
30th Jun 20231:40 pmRNSHolding(s) in Company
30th Jun 20231:35 pmRNSHolding(s) in Company
30th Jun 202310:11 amRNSDirector/PDMR Shareholding
29th Jun 20237:00 amRNSFY23 full year results
28th Jun 20235:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.